This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
CLOV Q2 Earnings In Line, Stock Falls on Raised Insurance BER View
by Zacks Equity Research
Clover Health's Q2 revenues rise 34%, but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.
BSXNegative Net Change WSTNegative Net Change MEDPNegative Net Change CLOVNegative Net Change
earnings medical medical-devices
COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised
by Zacks Equity Research
Cencora posts strong Q3 results with earnings and revenues surpassing estimates; raises FY25 EPS guidance on robust U.S. segment growth.
BSXNegative Net Change CORNegative Net Change WSTNegative Net Change MEDPNegative Net Change
earnings medical medical-devices
Are Options Traders Betting on a Big Move in BrightSpring Health Services Stock?
by Zacks Equity Research
Investors need to pay close attention to BrightSpring Health Services stock based on the movements in the options market lately.
BTSGNegative Net Change
medical medical-devices
Tidewater (TDW)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
TDWNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bio-Techne Q4 Earnings Beat Estimates, Gross Margin Down, Stock Falls
by Zacks Equity Research
TECH tops Q4 EPS estimates and posts solid revenues, but shrinking margins and operating loss drag shares lower.
BSXNegative Net Change TECHNegative Net Change MEDPNegative Net Change WGSPositive Net Change
earnings medical medical-devices
Should You Buy, Sell or Hold Hologic Stock Post Q3 Earnings?
by Moumi Mondal
HOLX rises post earnings beat, fueled by Diagnostics strength and Surgical growth. However, macro headwinds persist.
BDXPositive Net Change HOLXNegative Net Change GEHCNegative Net Change
medical medical-devices
Can Sustained Product Demand Drive BDX Stock Before Q3 Earnings?
by Zacks Equity Research
BD's third-quarter fiscal 2025 results are likely to benefit from product launches across Medical and Interventional segments, which drive strong revenue potential.
BDXPositive Net Change CAHNegative Net Change MCKNegative Net Change COONegative Net Change
earnings medical medical-devices
Can Solventum Sustain Growth Amid Tariff Headwinds in Q2 Earnings?
by Zacks Equity Research
SOLV's Q2 earnings are likely to test whether solid segment growth can offset tariff and ERP-related pressures.
CAHNegative Net Change MCKNegative Net Change CRMDNegative Net Change SOLVPositive Net Change
medical medical-devices
HIMS Stock Plunges Following Q2 Earnings Miss, Gross Margin Down
by Zacks Equity Research
Hims & Hers misses second-quarter 2025 EPS and revenue estimates as gross margin narrows, despite strong online sales and subscriber growth.
BSXNegative Net Change WSTNegative Net Change HIMSNegative Net Change GEHCNegative Net Change
earnings medical medical-devices
INSP Stock Plunges Despite Q2 Earnings Beat, Gross Margin Contracts
by Zacks Equity Research
Inspire Medical tops second-quarter 2025 earnings estimates and posts solid revenue growth, but trims 2025 guidance amid margin pressure.
BSXNegative Net Change WSTNegative Net Change INSPPositive Net Change GEHCNegative Net Change
earnings medical medical-devices
CVS Lifts 2025 Adjusted EPS Forecast Again: What's Driving the Move?
by Moumi Mondal
CVS Health boosts 2025 EPS guidance again as Health Care Benefits and PBM businesses drive growth.
AMZNPositive Net Change CVSNegative Net Change ELVPositive Net Change
medical medical-devices
Will GLP-1 Demand Drive MCK's Top Line This Earnings Season?
by Zacks Equity Research
MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.
CAHNegative Net Change MCKNegative Net Change COONegative Net Change CRMDNegative Net Change
medical medical-devices
ISRG's Ion Platform Sees Uptick in Utilization, Eyes Efficiency
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform posted 52% procedure growth in Q2, but rising system utilization and workflow efficiency now drive its profitability focus.
SYKPositive Net Change ISRGPositive Net Change ZBHNegative Net Change
medical medical-devices
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
by Zacks Equity Research
COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.
CAHNegative Net Change MCKNegative Net Change CORNegative Net Change CRMDNegative Net Change
medical medical-devices
AVTR Stock Declines as Q2 Earnings Miss Estimates, Revenues Down Y/Y
by Zacks Equity Research
Avantor stock dips more than 15% as Q2 EPS missed estimates, revenue declines year over year and lowers full-year guidance.
BSXNegative Net Change WSTNegative Net Change MEDPNegative Net Change AVTRPositive Net Change
earnings medical medical-devices
Central Garden (CENT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CENTNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
IDEXX Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
by Zacks Equity Research
IDXX posts double-digit Q2 revenue growth, beats EPS estimates and lifts the full-year outlook as margins rise sharply.
BSXNegative Net Change IDXXPositive Net Change MEDPNegative Net Change WGSPositive Net Change
earnings medical medical-devices
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.
TECHNegative Net Change CRMDNegative Net Change AMRXNegative Net Change GMABPositive Net Change
earnings medical medical-devices
DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
XRAY's Imaging strength and SureSmile growth might have lifted Q2 performance, but Byte's drag and macro pressures likely clouded the top-line momentum.
CAHNegative Net Change MCKNegative Net Change XRAYPositive Net Change CORNegative Net Change
medical medical-devices
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
by Urmimala Biswas
TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.
AZNNegative Net Change TXGNegative Net Change SOPHPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-estimates-revisions earnings-outlook earnings-preview earnings-report earnings-streak earnings-surprise healthcare medical medical-devices smart-health
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands
by Zacks Equity Research
OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.
BSXNegative Net Change WSTNegative Net Change OPKNo Net Change GEHCNegative Net Change
earnings medical medical-devices
Hims & Hers Stock to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
HIMS' second-quarter 2025 results are likely to benefit from subscriber momentum and digital care tools.
CAHNegative Net Change MCKNegative Net Change CRMDNegative Net Change HIMSNegative Net Change
earnings medical medical-devices
Can Veeva's Vault R&D Keep Its Lead Amid Rising AI Competition?
by Zacks Equity Research
VEEV leans on Vault R&D for growth as AI-native rivals rise, testing its edge in clinical and regulatory innovation.
DASTYPositive Net Change VEEVNegative Net Change SDGRPositive Net Change
medical medical-devices
TMDX Stock Gains Post Q2 Earnings & Revenue Beat, Margins Up
by Zacks Equity Research
TransMedics stock jumps 10.5% as Q2 EPS beats by 91.7%, revenue rises 37.7%, and operating margin expands 1230 basis points.
BSXNegative Net Change WSTNegative Net Change MEDPNegative Net Change TMDXPositive Net Change
earnings medical medical-devices
Do Options Traders Know Something About Aurora Cannabis Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ACB stock based on the movements in the options market lately.
ACBPositive Net Change
cannabis medical medical-devices